MRK - Merck & Co., Inc.
| Previous close | 91.18 |
| Open | 91.86 |
| Bid | 91.18 x 1000 |
| Ask | 91.67 x 2900 |
| Day's range | 91.14 - 91.37 |
| 52-week range | 72.05 - 92.64 |
| Volume | 1,416,961 |
| Avg. volume | 8,285,715 |
| Market cap | 232.55B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 25.52 |
| EPS (TTM) | 3.58 |
| Earnings date | 04 Feb 2020 |
| Forward dividend & yield | 2.44 (2.67%) |
| Ex-dividend date | 11 Dec 2019 |
| 1y target est | 99.06 |
- Zacks
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
- Zacks
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
- Zacks
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
- Zacks
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
- Zacks
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
- Zacks
Merck (MRK) Gains As Market Dips: What You Should Know
In the latest trading session, Merck (MRK) closed at $89.92, marking a +0.46% move from the previous day.
- Zacks
AstraZeneca to End Phase III Study on Fish Oil Heart Drug
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
- Zacks
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
- Business Wire
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review
FDA Accepts Regulatory Submission of sNDA for LYNPARZA as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer & Grants Priority Review
- Zacks
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
- Zacks
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
- Zacks
Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer
Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy
FDA Approves Merck's KEYTRUDA® for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
- Zacks
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study
Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.
- Zacks
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
- Zacks
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
- Zacks
Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study
Pfizer (PFE) and Merck KGaA's Bavencio meets the primary goal in a late-stage study evaluating it as a first-line maintenance therapy for metastatic urothelial carcinoma, a form of bladder cancer.
- Investing.com
Merck Weighs on Dow After Clinical Trial Miss
Investing.com - Drugmaker Merck was a drag on the Dow Jones in midday trading Tuesday as the blue-chip index struggled to follow the S&P; and Nasdaq into positive territory.
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $91.64, moving +0.42% from the previous trading session.
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
KEYTRUDA (pembrolizumab) in Combination w/Chemo Significantly Improved Progression-Free Survival Compared to Chemo Alone for Extensive Stage SCLC
- Simply Wall St.
What Does Merck & Co., Inc.'s (NYSE:MRK) P/E Ratio Tell You?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...
- Zacks
Leap Therapeutics Surges on License Agreement With BieGene
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
- Zacks
Amgen Stock Up in a Year on Pipeline & Biosimilar Progress
Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.
